AntiRadical is proud to announce its recent selection as a Defense TechConnect Innovation Awardee for its vascular therapeutic SanFlow. This is the third year in a row that AntiRadical's products have been honored with this award. SanFlow is being developed to: (1) correct vascular dysfunction and inflammatory reactions (2) prevent organ injuries and death in brain injuries, hemorrhagic shock, cancer, stroke, Alzheimer's Disease, COVID-19 infections and other conditions. SanFlow’s specific use in Prolonged Field Care, the top priority capability gap across the US Army, was highlighted at the recent Defense TechConnect 2021 Conference.
The annual TechConnect Innovation Awards recognize the top 15% of submitted Challenge technologies as ranked by the Selection Committee.
The 2021 Defense Techconnect presentation was entitiled: "SanFlow - A Drug for Prolonged Field Care that Corrects Vascular Dysfunction and Prevents Multi-Organ Injuries".
The 2020 Defense Techconnect presentation was entitled: "VACNO: A Therapeutic Adjunctive Treatment For COVID-19".
The 2019 Defense TechConnect presentation was entitled: "SanFlow: A Therapeutic Agent for Use in the Field for Traumatic Brain Injury".
To learn more about the Defense TechConnect Summit and Expo, one of the most well-attended Defense events of the year visit:
Innovation Award Recipient for use of SanFlow to correct vascular dysfunction, inflammatory reactions and/or cytokine storms that lead to organ damage including multi-organ failure in major medical conditions.
Innovation Award Recipient for use of SanFlow in severe traumatic brain injury in combat casualty care and in civilian populations.
Military Health System Research Symposium (MHSRS) Orlando, Florida 2019. Oral presentation: "A Neuroprotective Superoxide Dismutase / Catalase Mimetic Drug For Resuscitation After Traumatic Brain Injury Combined With Hemorrhagic Shock For Combat Casualty Care". https://mhsrs.amedd.army.mil/
Global Entrepreneurship Summit (GES-2019) The Hague, Netherlands. Company Presentation: “A drug for the treatment of cancer and brain injuries which could increase the quality of healthcare and decrease costs by up to $1 Trillion in the US”. AntiRadical was the sole company to receive media attention in a press article summarizing the Summit. GES-2019 was co-organized by the US Department of State. This is the link to the article in Diplomat Magazine summarizing the Summit: http://www.diplomatmagazine.eu/2019/06/09/ges-2019-draws-to-an-end/
Innovation supported by the US Army Medical Research and Materiel Command and by NINDS/NIH.